These findings are consistent with phase III NSCLC trials of gemcitabine-cisplatin, in which Grade 2 ALT elevations occurred in approximately 10% of patients and Grade 2 creatinine elevations in around 9%, while higher-grade events were uncommon [29]. The gene discussed is GPT; the disease is non-small cell lung carcinoma.